HCM is a genetic disease, usually caused by mutations in sarcomere proteins such as myosin, actin, tropomyosin, and myosin-binding protein C.
The American College of Cardiology (ACC) and the American Heart Association (AHA) have released a new clinical guideline for effectively managing individuals diagnosed with hypertrophic cardiomyopathy ...
Everyday Health on MSN
Your hypertrophic cardiomyopathy (HCM) symptoms: When to call your doctor and when to call 911
HCM symptoms can vary in severity. Learn which ones warrant a call to the doctor and which are emergencies.
Everyday Health on MSN
Hypertrophic cardiomyopathy (HCM) and implantable devices: What to know about ICDs (and other options)
Two types of implantable cardioverter defibrillators can reduce the risk of sudden cardiac death with HCM. Pacemakers and implantable loop recorders also may be options.
Myqorzo is expected to be available by the second half of January 2026. The Food and Drug Administration (FDA) has approved Myqorzo™ (aficamten) for the treatment of adults with symptomatic ...
For patients with hypertrophic cardiomyopathy that doesn’t improve with standard therapy, surgery may be the next choice. In France, a new study was conducted to compare the incidence of in-hospital ...
The emergence of novel pharmacotherapies, minimally-invasive procedures and gene-directed approaches shall fundamentally alter the Hypertrophic Cardiomyopathy therapeutic landscape. Amongst all ...
Please provide your email address to receive an email when new articles are posted on . Mavacamten presents dosing and drug-drug interaction challenges. A multidisciplinary approach featuring a ...
Cytokinetics received U.S. FDA approval for MYQORZO on December 19, 2025. The approval was based on the positive results from the pivotal Phase 3 clinical trial, SEQUOIA-HCM, published in the New ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved mavacamten for the treatment of symptomatic, obstructive hypertrophic cardiomyopathy, the first ...
Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden death in adolescents and initial detection is often difficult. A new UCSF study finds that Artificial Intelligence-enhanced ...
If you have hypertrophic cardiomyopathy (HCM), your heart struggles to work as well. This causes fatigue and other symptoms. Getting enough sleep is important for supporting your physical and mental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results